FDA advances Neuren's Phase III to next year
06 June, 2005 by Ruth BeranNZ-based Neuren (ASX:NEU) has received confirmation from the US Food and Drug Administration (FDA) that the company can bypass a previously planned Phase IIb study for its lead drug Glypromate and advance directly to a major Phase III efficacy study.
Phenomix closes US$40 million series B financing
03 June, 2005 by Ruth BeranPhenomix, based in Canberra and San Diego, has closed a US$40 million private placement of its series B preferred stock, with new US investors JPMorgan Partners and Delphi Ventures co-leading the financing.
Progen explains share price dip
03 June, 2005 by Ruth BeranBrisbane cancer-drug developer Progen (ASX:PGL) has responded to an ASX 'please explain' in response to its flagging share price, citing the expiry of listed options on May 31 and speculation of a larger than expected shortfall as possible.
Mesoblast tech may be used to treat injured AFL star
03 June, 2005 by Ruth BeranThe orthopaedic surgeon of an injured AFL football player is considering using Melbourne-based stem cell specialist Mesoblast's (ASX:MSB) technology to accelerate bone regeneration in the footballer's fractured leg, the company has claimed.
FDA approves GroPep-based biopharma product
02 June, 2005 by Ruth BeranA biopharmaceutical product that uses GroPep's (ASX:GRO) cell culture products in its manufacturing process has received US Food and Drug Administration (FDA) regulatory approval.
Domantis find expected to benefit Abbott
02 June, 2005 by Graeme O'NeillUK antibody therapeutics developer Domantis has pulled a double-headed rabbit out of the hat for its client, the big European pharma Abbott Laboratories.
Genesis Biomed boosts advisory board, starts CEO hunt
02 June, 2005 by Graeme O'NeillSydney-based Genesis Biomedical (ASX:GBL) is moving to raise its profile in the Australian biomedical marketplace, after appointing two more senior researchers to its new strategic advisory committee.
Biosignal nets global contact lens deal
01 June, 2005 by Ruth BeranSydney's Biosignal (ASX:BOS) and its partner, the Institute for Eye Research (IER), have closed a deal with an international contact lens manufacturer to develop anti-bacterial daily disposable and other frequent replacement contact lenses for eventual sale to the US and European markets.
We're out of start-up phase: Cryptome
01 June, 2005 by Ruth BeranEighteen months after its AUD$6.6 million IPO in November 2003, Melbourne-based Cryptome Pharmaceuticals (ASX:CRP) has achieved all of the objectives listed in its IPO prospectus and claims that it is no longer in the start-up phase.
Alchemia heartened by thumbs-up for Glaxo drug
31 May, 2005 by Graeme O'NeillShares in Brisbane biopharma Alchemia (ASX:ACL) rose 7 per cent today on news that the US Food and Drug Administration has approved GlaxoSmithKline's anti-thrombotic drug Arixtra in surgical patients at high risk of life-threatening venous blood clots.
AustCancer changes name, sets course for US
31 May, 2005 by Graeme O'NeillOncology drug developer Australian Cancer Technology (ASX:ACU) has changed its name to Avantogen, and flagged its intention to relocate its headquarters to San Diego, on the US west coast, within a few years.
Tissue Therapies patent accepted in Australia
31 May, 2005 by Ruth BeranThe core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
Biotech pioneer BresaGen resurrected as service company
30 May, 2005 by Graeme O'NeillThe dark clouds over venerable Adelaide biopharma BresaGen (ASX:BGN) have parted, revealing a little blue sky. But the resurrected company's business plan is focused on terra firma -- it is going back to its roots as a service company.
Cryptome in deal with German biotech Xantos
27 May, 2005 by Graeme O'NeillMelbourne drug discovery biotech Cryptome Pharmaceuticals (ASX:CRP) has turned on its income tap after signing a collaboration agreement with Germany's Xantos Biomedicine to validate Xantos' lead anti-cancer molecule.
New biopharma Apollo readies for lift-off
27 May, 2005 by Graeme O'NeillSydney-based biopharma Apollo Life Sciences lodged its prospectus with the ASX yesterday to raise AUD$9.5 million from its IPO in June.
